HealthSignals coverage organized by therapeutic area: oncology, cardio-metabolic disease, rare and genetic diseases, neuroscience, immunology and infectious diseases across Latin America and the United States.
HealthSignals coverage organized by therapeutic area: oncology, cardio-metabolic disease, rare and genetic diseases, neuroscience, immunology and infectious diseases across Latin America and the United States.
Pelacarsen reduced lipoprotein(a) (Lp(a)) by 78% in a Phase III trial of more than 8,300 adults yet produced no reduction in major adverse cardiovascular events, raising questions about whether lowering …
An international trial of 702 randomized adults found left bundle branch pacing (LBBP) lowered the hazard of death, heart failure hospitalization or pacing-induced cardiomyopathy by 59% (hazard ratio 0.41) versus …
Measles infections in the United States and Mexico have already exceeded all of 2025, with Pennsylvania recording five deaths and more than 1,000 infections as vaccine exemptions reach an all-time …
A matched cohort of 52,330 women aged 45 to 59 found no excess risk of heart attack, stroke, blood clots, or death over 12 years — with no meaningful difference …
With 55,792 confirmed measles cases and 77 deaths across the Americas in 2026, PAHO warns that upcoming religious mass gatherings in South America could accelerate transmission in a region where …
Novo Nordisk began distributing oral semaglutide 25 mg (Wegovy tablets) in Mexico’s private market on November 11, after COFEPRIS approval in August. The same day, an update to the national …
Bristol Myers Squibb and A.C.Camargo Cancer Center signed BMS’s first oncology risk-sharing agreement in Brazil, covering first-line ipilimumab plus nivolumab in lung cancer, with results assessed within 90 days of …
Costa Rica’s social security fund is running technical studies to choose a GLP-1 molecule for patients with diabetes, with obesity to follow. A diabetes decision is expected in November, as …
Phase III SAFFRON data show osimertinib plus savolitinib cut progression or death risk by 45% and death risk by 32% versus chemotherapy in MET-driven epidermal growth factor receptor-mutated non-small cell …
Phase III DeLLphi-305 data show tarlatamab plus durvalumab extended median overall survival to 21.1 months versus 12.7 months with durvalumab alone in extensive-stage small cell lung cancer maintenance.
You must be logged in to post a comment.